Table 1

Summary of the patient characteristics

Complete cohortSjögren’s syndrome n=83NSCS
n=65
Healthy donors n=12
Gender, F/M75/857/811/1
Age in years mean54 [55] (14.0)55 [56] (13.3)43 [44] (7.4)
[median] (SD)
Primary/ Secondary
Sjogren’s syndrome
74/9
Disease duration in years5.9 [3] (6.0)5.1 [3] (5.6)
Mean [median] (SD)
ESSDAI5.5 [5] (4.9)n/a
Mean [median] (SD)
Anti-Ro59%0%
Positive of total
Anti-La35%0%
Positive of total
Rheumatoid factor51%11%
Positive of total
Serum IgG (g/L)15.4 [14.0] (5.8)11.0 [11.1] (3.7)
Mean [median] (SD)
Serum IgA (g/L)2.9 [2.3] (1.8)2.8 [2.5] (2.4)
Mean [median] (SD)
Serum IgM (g/L)1.5 [1.1] (2.0)1.3 [1.1] (0.7)
Mean [median] (SD)
Serum C3 (g/L)1.2 [1.2] (0.3)1.5 [1.3] (1.3)
Mean [median] (SD)
Serum C4 (g/L)0.2 [0.2] (0.1)0.3 [0.3] (0.1)
Mean [median] (SD)
Lymphocytes count (x109/L)1.6 [1.5] (0.6)2.2 [2.1] (0.8)
Mean [median] (SD)
Treatments
Hydroxychloroquine
csDMARDs*
35/83
8/83
Steroids5/83
  • *csDMARDs other than hydroxychloroquine.

  • csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ESSDAI, EULAR Sjogren's syndrome disease activity index; NSCA, non-specific chronic sialadenitis.